Considerable Proportion of Seniors Have Asymptomatic Valvular Heart Disease
By Elana Gotkine HealthDay Reporter
TUESDAY, July 16, 2024 -- A considerable proportion of older adults without known valvular heart disease (VHD) have asymptomatic VHD, with age the only parameter associated with significant VHD, according to a study published online June 26 in the European Heart Journal: Cardiovascular Imaging.
Vasiliki Tsampasian, M.D., from Norwich Medical School at the University of East Anglia in the United Kingdom, and colleagues conducted a prospective cohort study between 2007 and 2016 to examine the prevalence and associated factors of asymptomatic VHD in individuals aged 60 years and older. Data were included for 4,237 participants.
The researchers found that VHD was diagnosed in 28.2 percent of patients. The most common types of VHD were regurgitation of the tricuspid, mitral, and aortic valves (13.8, 12.8, and 8.3 percent, respectively). The rate of prevalence of clinically significant VHD was 2.4 percent, with 2.2 and 0.2 percent moderate and severe, respectively. Mitral and aortic regurgitation were the most common. Age was the only parameter associated with significant VHD (odds ratio, 1.07 per one-year increment). To diagnose one clinically significant case of VHD, the number needed to scan was 42 and 15 for individuals aged 60 years and older and 75 years and older, respectively.
"These valuable data can lay the foundation for further epidemiological studies evaluating the burden of VHD in the community and the potential role of echocardiographic screening in the elderly population," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-17 03:15
Read more
- Preventing, Treating Sports Injuries in Kids: A Guide
- Abeona Therapeutics Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
- AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia
- Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
- A Cancer Diagnosis Takes Devastating Toll on Family Finances
- ASN: 1990 to 2021 Saw Global Rise in Chronic Kidney Disease Cases, Deaths in Women
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions